Event Details

Mergers & Acquisition - pain or gain?

Reducing the pain, increasing the gain and stopping PMs going insane

For people working in Portfolio & Project Management, Alliance Management and BD it looks like a busy time ahead. From big pharma through to small biotech or CRO you are likely to be directly involved with the inevitable chaos. Our speakers have all weathered the storm in recent years and will share their experiences on how to survive with your sanity intact!

 

 

Up to 7 CPD points are available to people attending the full meeting.

Speakers

Denise Moody: Senior Director, Project Management, Cycle Pharmaceuticals

Denise Moody

Denise started her career as a clinical biochemist who found that she was a natural project manager and loves project management with a passion. Denise has worked in the healthcare industry for over 25 years in a variety of companies e.g. Chiron, Bayer, Hexal, and PPD in project management roles encompassing R&D through to commercial and lifecycle management. She is currently Head of Operations and Project Management at Cycle Pharmaceuticals.

Tom Cartwright: Partner, Morgan, Lewis & Bockius UK LLP

Tom Cartwright

Tom is a partner in the London office of global law firm, Morgan Lewis & Bockius LLP.  He counsels UK and international private equity sponsors, sovereign wealth funds, and family offices on private equity investments and M&A transactions. He has particular expertise advising both publicly listed and private life science companies on M&A and  private equity transactions.

Tom often speaks about the current issues in the life sciences industry. He also writes about these topics for the UK and international trade press.

John Cogan: Head of Innovation & CTO, Kinapse

John Cogan

John has 30 years’ experience in the biopharma industry both within BioPharma and as a Consultant.  He has held global leadership positions in R&D IT, IT Shared Services and Chief Technology Officer roles, and been responsible for the delivery of major technology enabled organisational transformations across Pharma R&D.  John is a veteran of multiple mergers and acquisitions as both the acquiring and acquired party.  John has worked for and with many of the top biopharma companies throughout his career and holds a BSc in Chemistry and an MBA from Warwick Business School.

Mark Jones: Co-Founder, OneHE

Mark Jones

Dr Mark Jones in Co-Founder of OneHE, a social network for academics and educators (www.onehe.org). Over the last twenty years, he was worked in commercial director roles in the public, private and voluntary sectors for organisations including the University of York, BBC, Compass (a national healthcare charity) and Solaris, a European joint venture. He has been involved in six mergers and acquisitions.

Claire Baron, Deloitte

Claire Baron

Claire is a Senior Manager within Deloitte’s Transformation and Talent practice and delivers Change Management in largescale, global transformation programmes, specifically M&A. Claire has deep area expertise in Communications and Stakeholder Engagement. Claire holds a degree in Journalism from the Midrand Graduate Institute of South Africa and spent a year working in radio and television before moving to London to work as an executive producer. She moved into the business world to build on her commercial experience and found a passion for Human Capital consulting. Over the last nine years, her work at Deloitte has included Culture, Behaviour Change, Day 1 Communications, and post-merger integration Change Management. She was also part of the team awarded a Management Consulting Award for Change Management in the Private Sector for the work done on the three way asset swap between GSK and Novartis. Claire has worked across all sectors but maintains a keen interest in Pharmaceuticals with clients including GSK, CSL, Seqirus, AstraZeneca, Actelion, and Johnson & Johnson.

Janette Thomas and John Faulkes, PIPMG

Janette Thomas and John Faulkes

Janette Thomas (BSc, DiploD, PhD) is a director of PIPMG. Janette is Director of International Operations at Atlantic Healthcare plc since 2011. She is an experienced senior executive with 22 years in the pharmaceutical and biotechnology industry. She has led R&D and international pharmaceutical drug development projects including for GlaxoSmithKline plc (LSE:GSK), CELS Ltd, Gardant, Jomaa Pharma GmbH, Immodulon Therapeutics Ltd, and Horizon Discovery Group plc (LSE:HZD). Her experience includes leading research projects, manufacturing outsourcing, large multinational consortia, and multinational pharmaceutical projects. Janette has a Diploma in Company Direction from the Institute of Directors, a PhD from University of Leicester, UK, and post doctoral research at Cambridge University, UK. Janette has been a Board member and part of the PIPMG executive committee for over 10 years and has been involved in all areas of PIPMG activity - in particular looking after PIPMG finances and long term strategy.

John Faulkes began his career as a scientist in Immunology Diagnostics within the Wellcome Foundation (now GSK).  He moved after some years to a new career in human resources as a trainer, team coach and eventually a learning and development Business Partner. He became a consultant in the 1990's, offering organization development, team building, skills training / coaching, instructional design and coordination.  In 2001, he co-founded PPMLD Ltd with Ralph White, which specialises in enhancing collaborative working in life sciences – in particular, cross-functional project management and alliance / CRO outsourcing partnerships.  John is also highly experienced in developing online, interactive support for learning and continues to innovate as this technology evolves.

Colin Gaynor: Project Manager, AstraZeneca

Colin Gaynor

Colin Gaynor is a Project Manager within AstraZeneca (aligned to Oncology), driving global cross-functional teams to deliver assets from Lead Optimisation (pre-clinical) stage, through to Phase 3 development. He has circa 20 years experience of pharmaceutical drug development and supply chain management, across a broad spectrum of disease areas (including Oncology, Respiratory and Cardiovascular), and has worked extensively on alliance management project and in-licensed assets.

Originally qualified as a pharmacist by profession, he gained a PhD in neuropharmacology (at Aston University) before moving into Project Management within pharmaceutical industry. Being results focused and highly collaborative, he recognises and embraces the value of flexible thinking, strong leadership and stakeholder management to drive informed decision-making - with the ultimate goal of bringing new and innovative medicines to patients. 

Denise Moody: Senior Director, Project Management, Cycle Pharmaceuticals

Denise Moody

Denise started her career as a clinical biochemist who found that she was a natural project manager and loves project management with a passion. Denise has worked in the healthcare industry for over 25 years in a variety of companies e.g. Chiron, Bayer, Hexal, and PPD in project management roles encompassing R&D through to commercial and lifecycle management. She is currently Head of Operations and Project Management at Cycle Pharmaceuticals.

Event Agenda

2nd May 2019

Time Item Speaker
08:45 Registration and networking
09:20 Welcome and Introduction to PIPMG Denise Moody, Cycle Pharmaceuticals
09:30 What companies need to do to get ready for M&A? Tom Cartwright, Morgan, Lewis & Bockius UK LLP
10:10 Challenges when companies remain as different operating entities John Cogan, Kinapse
10:50 Refreshments and networking
11:20 Critical success factors for a successful merger - An overview of the latest literature on mergers and acquisitions plus an insight on what not to do. Mark Jones, OneHE
12:00 Human Capital aspects of an integration - Did you know that merger failure is less likely to be caused by buying the wrong business – it’s more about how it is integrated and the people? What are the common pitfalls faced when integrating companies? What does Deloitte’s research say and how can we learn from previous experience? This session will examine how to effectively tackle the people and culture change, with Claire sharing key challenges observed from previous integrations and principles for successful mergers. Claire Baron, Deloitte
12:40 Lunch and networking
13:30 How would you get ready for due diligence - what is the role of the PM? What do Biotech's think is required? Janette Thomas and John Faulkes, PIPMG
14:20 Marriage of Equals – How different can we be? - Colin will draw upon personal experiences and those from colleagues involved in the M&A’s field to briefly explore the reasons why companies might follow this approach despite data to indicate their limited success rates. Furthermore, he will share some insights on how organisations and project managers can mitigate against some of the associated risks. Colin Gaynor, AstraZeneca
15:00 Refreshments and networking
15:30 Mergers and Acquisitions, a personal viewpoint - Having survived 7 mergers/acquisitions, Denise will provide a private and personal insight into how she not only survived but also developed in terms of her skills and career. Denise Moody, Cycle Pharmaceuticals
16:10 Panel discussion All Speakers
17:00 Closing remarks PIPMG Committee
17:15 Networking drinks
18:15 Meeting close

Venue Details

The meeting will be held on 2nd May 2019 at: 2 New Street Square, London, EC4A 3BZ, United Kingdom, and will start at 09:00.